Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2016

01-04-2016 | Original Article

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

Authors: Varun Goel, Eunju Hurh, Andrew Stein, Jerry Nedelman, Jocelyn Zhou, Ovidiu Chiparus, Pai-Hsi Huang, Sven Gogov, Dalila Sellami

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2016

Login to get access

Abstract

Purpose

Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate effects.

Methods

PK data from five phase 1 or 2 studies (N = 436) in the dose range from 100 to 3000 mg were analyzed using NONMEM. A two-compartment base model with first-order absorption, lag time, linear elimination, and bioavailability that decreased with dose was updated to describe the PK of sonidegib. Covariate analyses were performed and were incorporated into the population PK full model.

Results

The base and full models were robust with a good fit to the study data. Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %). Clinically relevant covariate effects were: A high-fat meal increased sonidegib bioavailability fivefold, healthy volunteers had threefold higher clearance, sonidegib bioavailability decreased with increasing dose levels, and PPI coadministration reduced sonidegib bioavailability by 30 %. Sonidegib PK was not significantly impacted by baseline age, weight, total bilirubin, alanine aminotransferase, albumin, creatinine clearance, gender, and ethnicity (Western countries versus Japanese).

Conclusion

No dose adjustment is needed for mild hepatic impairment, mild and moderate renal impairment, age, weight, gender, or ethnicity. This population PK model adequately characterizes sonidegib PK characteristics and can be used for various simulations and applications.
Appendix
Available only for authorised users
Literature
1.
go back to reference di Magliano MP, Hebrok M (2003) Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3(12):903–911CrossRef di Magliano MP, Hebrok M (2003) Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3(12):903–911CrossRef
2.
go back to reference McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114CrossRefPubMed McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114CrossRefPubMed
3.
go back to reference Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805(2):181–208PubMed Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805(2):181–208PubMed
5.
go back to reference Buonamici S et al (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2(51):5170 Buonamici S et al (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2(51):5170
6.
go back to reference Rodon J et al (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumours. Clin Cancer Res 20(7):1900–1909CrossRefPubMed Rodon J et al (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumours. Clin Cancer Res 20(7):1900–1909CrossRefPubMed
7.
go back to reference Slade I et al (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 10(2):337–342CrossRefPubMed Slade I et al (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 10(2):337–342CrossRefPubMed
8.
go back to reference Zurawel RH et al (2000) Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27(1):44–51CrossRefPubMed Zurawel RH et al (2000) Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27(1):44–51CrossRefPubMed
9.
go back to reference Xie J et al (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90–92CrossRefPubMed Xie J et al (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90–92CrossRefPubMed
10.
go back to reference Reifenberger J et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152(1):43–51CrossRefPubMed Reifenberger J et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152(1):43–51CrossRefPubMed
11.
go back to reference Ling G et al (2001) PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20(53):7770–7778CrossRefPubMed Ling G et al (2001) PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20(53):7770–7778CrossRefPubMed
13.
go back to reference Migden MR et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716–728CrossRefPubMed Migden MR et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716–728CrossRefPubMed
14.
go back to reference Zollinger M et al (2014) Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74(1):63–75CrossRefPubMed Zollinger M et al (2014) Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74(1):63–75CrossRefPubMed
15.
go back to reference Novartis Pharmaceuticals Corporation Data on File (2015) Novartis Pharmaceuticals Corporation Data on File (2015)
16.
go back to reference Zhou J, Hurh E, Emotte C, Winter S, Quinlan M, Austin T, Kalambakas S, Wang Y (2014) Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug-drug interaction study with rifampicin and ketoconazole in healthy subjects. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, 2014. abstract LBI-021 Zhou J, Hurh E, Emotte C, Winter S, Quinlan M, Austin T, Kalambakas S, Wang Y (2014) Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug-drug interaction study with rifampicin and ketoconazole in healthy subjects. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, 2014. abstract LBI-021
17.
go back to reference Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(1):14–26CrossRefPubMed Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(1):14–26CrossRefPubMed
18.
go back to reference Gibaldi M, Perrier D (1972) Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci 61(6):952–954CrossRefPubMed Gibaldi M, Perrier D (1972) Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci 61(6):952–954CrossRefPubMed
19.
go back to reference Gastonguay M (2011) full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe 2011. A16 Gastonguay M (2011) full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe 2011. A16
Metadata
Title
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
Authors
Varun Goel
Eunju Hurh
Andrew Stein
Jerry Nedelman
Jocelyn Zhou
Ovidiu Chiparus
Pai-Hsi Huang
Sven Gogov
Dalila Sellami
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-2982-1

Other articles of this Issue 4/2016

Cancer Chemotherapy and Pharmacology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine